Artemisinin-resistant falciparum malaria, defined by a slow-clearance phenotype and the presence of kelch13 mutants, has emerged in the Greater Mekong Subregion. Naturally acquired immunity to malaria clears parasites independent of antimalarial drugs. We hypothesized that between-and within-population variations in host immunity influence parasite clearance after artemisinin treatment and the interpretation of emerging artemisinin resistance. Antibodies specific to 12 Plasmodium falciparum sporozoite and blood-stage antigens were determined in 959 patients (from 11 sites in Southeast Asia) participating in a multinational cohort study assessing parasite clearance half-life (PCt 1/2 ) after artesunate treatment and kelch13 mutations. Linear mixed-effects modeling of pooled individual patient data assessed the association between antibody responses and PCt 1/2. P. falciparum antibodies were lowest in areas where the prevalence of kelch13 mutations and slow PCt 1/2 were highest [Spearman ρ = −0.90 (95% confidence interval, −0.97, −0.65), and Spearman ρ = −0.94 (95% confidence interval, −0.98, −0.77), respectively]. P. falciparum antibodies were associated with faster PCt 1/2 (mean difference in PCt 1/2 according to seropositivity, −0.16 to −0.65 h, depending on antigen); antibodies have a greater effect on the clearance of kelch13 mutant compared with wild-type parasites (mean difference in PCt 1/2 according to seropositivity, −0.22 to −0.61 h faster in kelch13 mutants compared with wild-type parasites). Naturally acquired immunity accelerates the clearance of artemisininresistant parasites in patients with falciparum malaria and may confound the current working definition of artemisinin resistance. Immunity may also play an important role in the emergence and transmission potential of artemisinin-resistant parasites.
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malaria | artemisinin | drug resistance | immunity | serology A rtemisinin combination therapy (ACT), recommended by the World Health Organization (WHO) as first-line treatment of Plasmodium falciparum malaria, was used to treat 337 million patients with malaria in 2014 (1) . Global malaria mortality and morbidity have declined in recent years, largely as a result of increased deployment of insecticide-treated bed-nets and ACTs (1) . Artemisinin resistance, defined by slow parasite clearance after treatment with an artemisinin derivative, was initially reported in 2007 in Western Cambodia (2, 3) . Further independent reports of the slow-clearing phenotype spreading, or emerging independently, came from other areas of Western Cambodia, Thailand, Myanmar, and Vietnam (4-7). In 2014, mutations in the "propeller" region of a P. falciparum kelch protein (encoded by the kelch13 gene) were identified as molecular markers of artemisinin resistance based on their associations with the slow-clearance phenotype (8) . Recently, both the slow-clearance phenotype, defined by a long parasite clearance half-life (PCt 1/2 ) after artemisinin treatment (9) , and kelch13 mutations were reported by the Tracking Resistance to Artemisinin Collaboration (TRAC), a multinational trial of artesunate efficacy (10) . TRAC confirmed that artemisinin-resistant falciparum malaria is firmly established in Western Cambodia, Thailand, Eastern Significance Slow-clearing artemisinin-resistant malaria parasites are now well established in the Greater Mekong Subregion. This large multinational therapy efficacy study incorporating clinical data, molecular drug-resistance markers, and immune profiling aimed to understand how variations in population levels of naturally acquired malarial immunity affect the slow-clearing phenotype, emergence of artemisinin resistance-associated mutations, and assessment of the geographical spread of artemisinin resistance. We found that slowclearing mutant parasites occur at higher frequencies in areas where immunity is lowest, patients with higher immunity have faster clearance times, and immunity has the greatest effect on clearance in patients with slow-clearing mutant parasites. Immunity plays an important role in the emergence of resistant parasites and can confound the World Health Organization's phenotype and genotype definitions of artemisinin resistance.
Myanmar, and Southern Vietnam, and is emerging in Northern Cambodia and Southern Laos, but it found no evidence for artemisinin resistance in Africa (10) .
To facilitate monitoring and surveillance of artemisinin resistance, the WHO now defines confirmed partial artemisinin resistance as ≥5% of P. falciparum patients carrying kelch13 mutations associated with either persistent parasitemia on day 3 or a PCt 1/2 ≥5 h after artemisinin treatment (11) . Suspected artemisinin resistance is defined as ≥5% of patients with P. falciparum carrying kelch13 resistance-associated mutations, ≥10% of patients with parasitemia at day 3, or ≥10% of patients with a PCt 1/2 ≥5 h after treatment (11) . Although detection of molecular markers is unequivocal, there is substantial interindividual variability in parasite clearance. In vivo responsiveness to antimalarials is influenced by additional factors such as patient pharmacokinetic profiles, life cycle stage distribution of the parasites, and levels of host immunity (12) . Thus, the predictive values of both the PCt 1/2 ≥5 h cutoff and the kelch13 mutations in assessing artemisinin resistance may differ, depending on the contributions of these confounding factors.
Naturally acquired immunity to malaria develops after repeated exposure to parasites, and is acquired faster in high-compared with low-transmission areas (13) . P. falciparum antibodies are an important component of immunity and can target the sporozoite stage, reducing transmission and infection, and blood-stage parasites (merozoites, infected erythrocytes), reducing parasite multiplication and increasing parasite clearance rates, thereby suppressing parasite densities and clinical symptoms (14, 15) . Immunity may therefore confound the interpretation of parasite clearance measures in drugefficacy studies. The operational implications of an effect of host immunity on parasite clearance measures are that in populations with high levels of immunity and faster parasite clearance, early signs of low-grade drug resistance could go undetected, and conversely, that in populations with lower immunity and slower parasite clearance, a false impression of reduced drug efficacy could arise (16) (17) (18) . The available immunological evidence for this comes from previous single-study-site investigations, predominantly in hightransmission settings in Africa, which have reported conflicting associations between immunity and treatment failure to historical first-line treatments (e.g., chloroquine, sulfadoxine-pyrimethamine) and ACTs (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) . Of the four single-site studies looking at artemisinin derivatives, all examined ACT, where associations may be confounded by the partner drug, and all were performed in areas before the emergence of artemisinin resistance or in areas where resistance is yet to arise (24) (25) (26) (27) . Only one of these studies investigated an outcome measure included in the current WHO definition of artemisinin resistance (PCt 1/2 ) and found an unquantified inverse correlation (25) . However, single-site studies in areas in which resistance has yet to emerge fail to encapsulate between-and withinpopulation variations in malarial immunity and frequencies of kelch13 mutations. We hypothesize that between-and withinpopulation variations in host immunity influence parasite clearance after artemisinin treatment, confounding the current WHO working definitions of artemisinin resistance, and consequently the interpretation of the geographical spread of artemisinin resistance. In this multinational study, which includes multiple different transmission settings with varying frequencies of kelch13 mutations, we determined levels of antibodies specific for a panel of P. falciparum antigens and quantified their effect on PCt 1/2 , a key parameter in the WHO definition of artemisinin resistance after exposure to artesunate alone.
Methods
Study Design and Procedures. We studied plasma samples from 959 (of 985) patients with high parasitemia from 11 Southeast Asian sites (SI Appendix, Fig. S1 , text S1) participating in the TRAC multicenter drug-efficacy randomized control trial. Informed consent was obtained from all patients, and ethical approval was granted by the Oxford Tropical Research Ethics Committee (06/11), Alfred Hospital Committee for Ethics, Australia (485/12) (10). Participants received either 2 or 4 mg/kg artesunate for 3 d, followed by a full course of an ACT.
The initial study aimed to enroll 120 patients at each study site, which was achieved in six of the 11 Southeast Asian sites. Patients aged 0.5-65 y with uncomplicated falciparum malaria (parasitemia between 10,000 and 200,000/μL) and fever/history of fever were included. Blood smears were taken for malaria parasite counts at 0, 4, 6, 8, and 12 h, and then every 6 h until two consecutive counts were negative.
Immunoassays. At enrolment, plasma concentrations of total antigen-specific IgG were measured for recombinant P. falciparum merozoite, and sporozoite antigens using ELISAs, and IgG to the surface of P. falciparum-infected erythrocytes (3D7 strain) containing pigmented trophozoites, as previously described (SI Appendix, text S1).
Statistical Analysis. Definitions and methods are detailed in the SI Appendix, text S1. Briefly, the primary endpoint, PCt 1/2 (h) was derived from the parasite clearance estimator (9) . PCt 1/2 is a standardized measure of parasite clearance after antimalarial treatment and is the time needed for parasitemia to be reduced by half during the log-linear phase of parasite clearance. It is independent of initial parasitemia and excludes potential confounding of changes in parasite density after antimalarial drug administration (9) . Metaanalysis of the differences in mean PCt 1/2 according to sero-positivity was performed to provide estimates for each study site and for the overall cohort and heterogeneity was evaluated by the I 2 value. Linear mixed-effects modeling on the pooled individual patient data (adjusting for age and total dose of artesunate, and including a random effect for study site) was performed to assess the association between each antibody response and PCt 1/2. Interactions between kelch13 (defined as any mutation above amino acid position 440 with a median PCt 1/2 ≥5 h and present in at least 5 individuals) and antibody response were assessed using a likelihood ratio test.
Results
The study included 959 patients with falciparum malaria in 11 sites in Southeast Asia (Table 1) . P. falciparum densities showed no geographical patterns (SI Appendix, Fig. S2 ), whereas median PCt 1/2 values of ≥5 h and kelch13 mutation prevalence >50% were found only in Western Cambodia (Pailin and Pursat) and Thailand (Ranong and Srisaket) (10) ( Table 1 ). The prevalence of gametocytemia was also highest in Western Cambodia (Pailin and Pursat) ( To assess whether between-population variations in immunity are associated with the emergence of resistance, we plotted PCt 1/2 values and the prevalence of patients carrying kelch13 mutations that confer artemisinin resistance (kelch13 mutants) against a composite measure of blood-stage immunity for each study site (Fig. 2) . We observed a strong inverse correlation between We then investigated the association between immunity and PCt 1/2 by initially performing a meta-analysis for each antigen, plotting mean difference (and 95% CI) in PCt 1/2 in antibodypositive vs. antibody-negative patients at each study site in order of increasing resistance (and decreasing immunity). The largest magnitudes of effect between antibodies and PCt 1/2 were observed for sites with the highest prevalence of kelch13 mutations (Ranong and Srisaket in Thailand, Pursat and Pailin in Cambodia), as well as Ramu in Bangladesh (SI Appendix, Fig. S5 ), which had some of the highest levels of blood-stage immunity and where kelch13 mutations have not been found (Fig. 2) . In unadjusted pooled results, seropositivity was associated with reduced PCt 1/2, ranging from −0.10 (MSP1 19 ) to −0.29 h (MSP2 3D7 ) with low to moderate heterogeneity in the association between P. falciparum antibody response and PCt 1/2 between study sites [median I 2 (IQR) of all individual meta-analyses = 17.7% (1.7-32.5)].
Because of the limited heterogeneity, we estimated the magnitude of effect for each antibody response on PCt 1/2 by performing linear mixed-effects modeling of the pooled individual data, adjusting for the confounders of age and artesunate dose. Table 2 ). We then evaluated whether the observed association between immunity and PCt 1/2 was modified by the presence of a kelch13 mutation. Analyses of interactions showed that antibody positivity was associated with a reduced PCt 1/2 , and that for some antigens, the strongest magnitude of effect was observed in patients with slow-clearing kelch13 mutants compared with those with fast-clearing wild-type parasites (Table 2 ). For example, AMA1 seronegative patients with wildtype parasites had a mean PCt 1/2 of 2.85 h, and the effect of AMA1 antibodies on PCt 1/2 were negligible: mean difference (95% CI) in PCt 1/2 was −0.07 h (−0.43, 0.28 h; P = 0.693). In contrast, AMA1-seronegative patients with kelch13 mutant parasites had a longer mean PCt 1/2 of 6.95 h, and the effect of AMA1 antibodies was clinically and statistically significant: mean difference, −0.73 h (95% CI, −1.11, −0.35 h; P = 0.0001). Other examples whereby the effect of seropositivity on PCt 1/2 was >0.2 h in kelch13 mutants compared with wild-types were Rh2, MSP3, MSP6, and MSP7 (all P < 0.0136; Table 2 ). Analyses were also conducted using antibody levels, rather than seropositivity, with similar results (SI Appendix, p. 19).
Discussion
In this multinational study of malarial immunity and emergence of artemisinin resistance to date, we show that naturally acquired immunity to P. falciparum varies across populations and is lowest in areas where the prevalence of kelch13 mutations and slow parasite clearance phenotype are highest. P. falciparum antibody titers are associated positively with faster parasite clearance rates in these areas of relatively low immunity, and P. falciparum antibodies have the greatest effect on parasite clearance rates in the presence of kelch13 mutations. These findings suggest that host immunity contributes to the emergence and clearance of drug-resistant parasites and have implications for our understanding of the evolution of drug resistance, the spread of drug resistance, and the WHO operational definitions of artemisinin resistance.
The Greater Mekong Subregion, and in particular Western Cambodia, has been the epicenter for the emergence of drugresistant malaria, with resistance to previous first-line treatments for malaria (e.g., chloroquine, sulfadoxine-pyrimethamine) emerging in the region. Our data show that the highest prevalence of kelch13 resistance-associated mutations were found in sites in Western Cambodia and Thailand, regions where transmission (measured by antibodies to CSP) and P. falciparum blood-stage antibodies was lowest. In areas with low levels of protective bloodstage immunity, P. falciparum infections are more likely to progress to symptomatic disease states, which are subsequently treated, Fig. S2 and Fig. 2 , respectively. † A kelch13 mutation was defined as any mutation above amino acid position 440 with a median PCt 1/2 ≥ 5 h and present in at least 5 individuals (10). Discrepancies in numbers of total patients are a result of the presence of mixed infection (both wild-type and mutant alleles present) and/or missing genotypes.
exposing parasite populations in these areas to increased drug pressure. Furthermore, low levels of immunity may contribute to the emergence of kelch13 mutations through mechanisms independent of drug pressure. Initially unfit drug-resistant mutant parasites may be better able to persist in areas of low transmission and low immunity compared with areas of high transmission and high immunity, where there is competition from fitter wild-type parasites and increased recombination breakdown of multigenic resistance mechanisms (29) . Studies on the genetic architecture of parasites in the TRAC study suggest lower rates of recombination in Western Cambodia and Eastern Thailand, areas where we observed the lowest levels of anti-sporozoite and antiblood-stage immunity (30) . Low levels of immunity may also facilitate the transmission of resistant parasites from humans to mosquitoes, as low levels of blood-stage immunity increase the probability of gametocyte production (31) . Indeed, in the Greater Mekong Subregion, we observed some of the highest prevalences of gametocytemia and kelch13 mutants in areas with the lowest levels of immunity (e.g., Pursat, Pailin, Mae Sot). These immunological and genetic data from the TRAC study implicate low P. falciparum transmission intensity and low immunity in the emergence of mutations that confer artemisinin resistance in the Greater Mekong Subregion and inform our understanding of the evolution and emergence of antimalarial drug resistance in the region.
A delay in parasite clearance after artemisinin treatment is the first sign of emerging resistance before actual treatment failure is observed. In these early stages of emerging resistance, we found that P. falciparum blood-stage antibodies were associated with faster PCt 1/2 after artemisinin treatment, even in low-transmission areas where immunity was lowest. Immunity is therefore an important contributor to variations in PCt 1/2 between patients. The mean effect of immunity on PCt 1/2 for associated antigens was around 30 min, with a maximum 95% CI of the true population mean of 1 h, which is striking given the rapid action of artemisinins [median (IQR) PCt 1/2 of 4,008 profiles, 3.11 (2.33-4.24 h)] (9). The accurate measurement of PCt 1/2 requires frequent sampling and accurate counting of parasitemia, which is operationally challenging and not available in all settings (9) . However, PCt 1/2 allows for a detailed understanding of artemisinin resistance and prompted the WHO to endorse its use (32) . According to the WHO definitions, shifts in the distribution of PCt 1/2 of 30 min to 1 h may have operational implications in the assessment of artemisinin resistance (32) .
First, PCt 1/2 ≥ 5 h is a key parameter in validating which kelch13 mutations (108 nonsynonymous mutations have been identified to date) are associated with resistance, and the effect of immunity on PCt 1/2 may result in the misclassification of kelch13 resistance mutations, particularly as different kelch13 mutations have varying effects on the clearance phenotype (e.g., reported PCt 1/2 range, 0.6-13.8 h (10) . Clear examples of this in the TRAC study are the mutations F446I, N525D, and G538V, with mean PCt 1/2 of 4.60, 4.70, and 4.65 h, respectively, and classified as mutations that are not associated with resistance but are less than 30 min away from meeting the definition of a resistance-associated mutation (10) .
Second, immunity may result in misclassification of artemisinin resistance in patients whose PCt 1/2 is within 30 min of the PCt 1/2 cut off of 5 h, which corresponded to 11.5% of patients (4.3% and 18.5% of patients with wild-type and kelch13 mutant parasites, respectively). The extent of this patient misclassification is concerning, given that these proportions are close to the current WHO Camb. Camb.
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Parasite clearance half-life x10 (h) definitions of artemisinin resistance in malaria-endemic populations (confirmed partial resistance, ≥5% of patients with kelch13 mutants plus PCt 1/2 ≥ 5 h; suspected partial resistance, ≥5% with kelch13 mutants or ≥10% with PCt 1/2 ≥ 5 h), and misclassification of the presence of artemisinin resistance at the population level will be in areas of emerging artemisinin resistance, where the distribution of PCt 1/2 values are on the cusp of the 5-h PCt 1/2 cutoff included in the population prevalence definition (SI Appendix, Fig. S6 ). In populations with low immunity, a shift toward longer PCt 1/2 may lead to misclassification of emerging resistance, whereas in populations with high immunity, immune-clearance mechanisms may counteract the propensity for increasing PCt 1/2 after the emergence of resistant parasites and a conclusion that the population is free from resistance. The potential for missing the emergence of resistance will be greatest where the prevalent kelch13 mutations confer milder effects on PCt 1/2 . For example, on the ThailandMyanmar border, the "milder" E252Q mutation predominated as artemisinin resistance emerged, but has now been overtaken by the more "extreme" C580Y mutation. In northern Myanmar, the "milder" F446I now predominates as resistance emerges (33) . Potential conclusions that there is no resistance in areas where resistance is beginning to emerge are of significant concern. The confounding effect of immunity in the WHO definitions of artemisinin resistance therefore warrants consideration. For example, in highertransmission areas, a lowering of the population prevalence of a PCt 1/2 ≥ 5 h cutoff from 10% to 5% may be justified. Further studies on the sensitivity and specificity of these definitions in areas of varying immunity, and their operational implications, are required. Interestingly, we found some evidence that antibodies have little effect on fast-clearing wild-type infections, but a significant effect on PCt 1/2 in patients with slow-clearing kelch13 mutant parasites. This may reflect differences in parasite clearance mechanisms between the two strains after treatment with artemisinins. Exposure of wild-type ring-stage parasites to artemisinin derivatives damages and kills the parasite, with the spleen rapidly removing damaged intraerythrocytic ring-stage parasites (a process termed "pitting"), returning the once-infected erythrocytes to circulation (34, 35) . Pitting is the main mechanism of parasite clearance after artesunate treatment in nonimmune children in high-transmission areas, whereas in older semi-immune children, immune-mediated parasite clearance mechanisms predominate and parasite clearance by pitting is reduced (36) . Therefore, both immune-independent and immune-dependent mechanisms of parasite clearance will result in fast-clearance of wild-type infections regardless of immune status. Conversely, resistant kelch13 mutant parasites remain phenotypically unchanged after exposure to artemisinin derivatives (37) and will be less susceptible to pitting, with immune-dependent clearance mechanisms playing a greater role in parasite clearance. Kelch13 mutant parasites that are able to survive after exposure to artemisinins and progress to trophozoites and schizonts (37) can then be cleared through removal of opsonized whole P. falciparuminfected erythrocytes or by opsonic phagocytosis of free merozoites (38) (39) (40) . In addition, antibodies can act to inhibit invasion or act as targets for complement deposition and merozoite lysis, and in this way reduce parasite multiplication rates (41, 42) . Immunity therefore has not only more time but a greater range of mechanisms to effectively increase parasite clearance rates of slowclearing kelch13 parasites through immune-mediated mechanisms.
A major strength of this study is that it was conducted across multiple populations and transmission settings and included areas in which artemisinin resistance is prevalent and spreading. In addition, we assessed antibody responses against a panel of biomarkers of P. falciparum transmission and blood-stage immunity, including both merozoite antigens that are relatively conserved across parasite populations, as well as highly genetically-diverse variant surface antigens. Most antigens were highly immunogenic, with differential recognition according to geographical site and associated with decreases in PCt 1/2 . Although heterogeneity was observed in the association between antibody responses to individual antigens and PCt 1/2 across study sites, statistical heterogeneity was generally low, validating the generalizability of our findings to other studies and populations. As antibodies determined by ELISA do not produce a common metric measurement, seropositivity data were used in our primary analysis to quantify the effect of immunity on PCt 1/2 to ensure maximum comparability and translatability to future studies. We have, however, shown that the same conclusions would have been reached if we analyzed antibody levels, rather than seropositivity (SI p26). We have identified a number of relatively conserved merozoite antigens that could be used in future therapeutic efficacy studies of artemisinin resistance. The largest magnitudes of effect were seen with AMA1 and MSP3, vaccine candidates that are established biomarkers of protective immunity across different populations (15) , and MSP2, MSP6, and MSP7; interestingly, relatively small effects were observed for MSP1 19 , which is often used, together with AMA1, in serosurveillance studies. Given the variations with respect to individual antigens in populations, future therapeutic efficacy studies should consider using three or more antigens to remove the potential for Linear mixed-effects model, with a random effect for study site and adjustments made for age and artesunate dose, estimate PCt 1/2 in patients who are seronegative and the mean difference in PCt 1/2 in patients who are seropositive. To examine whether this association was modified by kelch13 mutant or wildtype status, an interaction term between kelch13 and antibody variable was assessed by comparing models with and without the interaction term, using a likelihood ratio test. P values for interaction: AMA1, P = 0.012; Rh2, P = 0.025; EB175 RII , P = 0.272; EB175 RIII-V , P = 0.385; MSP1 19 , P = 0.535; MSP2 3D7 , P = 0.789; MSP2 FC27 , P = 0.628; MSP3, P = 0.186; MSP6, P = 0.282; MSP7, P = 0.068; VSA 3D7 , P = 0.121. Models run with continuous log 2 antibody responses can be found in SI Appendix, Table S1 .
spurious associations, and to adjust parasite clearance measures accurately for the confounding effects of immunity and provide the most correct estimates of the prevalence of artemisinin-resistant falciparum malaria in populations.
Our study establishes a role for naturally acquired immunity in the emergence and clearance of artemisinin-resistant parasites. These results inform our understanding of the evolution of drug resistance in the region and have practical implications by providing important parameters for consideration not only in molecular and population definitions of artemisinin resistance but also serological tools to inform artemisinin resistance monitoring and surveillance. The observation that resistance is emerging in areas of low immunity is particularly relevant given that P. falciparum transmission is declining in many areas including the Greater Mekong Subregion because of the scale-up of artemisinin resistance containment programs and malaria control programs to achieve national malaria elimination targets (11) . As reductions in P. falciparum transmission will be accompanied by reductions in immunity, it will be important to understand temporal trends in changing immunity and their effect on the emergence of kelch13 mutations and the interpretation of PCt 1/2 values, and consequent assessment of emerging artemisinin resistance. Accurate assessment of the frequency of artemisinin resistance in populations is essential for timely instigation of artemisinin resistance containment and elimination strategies to impede the expansion of artemisinin-resistant parasite populations and to preserve the artemisinin derivatives for the treatment of falciparum malaria.
